{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:13:53Z","timestamp":1792761233894,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>[18F]FDG-PET\/CT\u00a0is used for diagnosing metastatic infections in <jats:italic>Staphylococcus aureus<\/jats:italic> bacteremia (SAB) and guidance of antibiotic treatment. The impact of [18F]FDG-PET\/CT\u00a0on outcomes remains to be determined. The aim of this systematic review was to summarize the effects of [18F]FDG-PET\/CT\u00a0on all-cause mortality and new diagnostic findingsin SAB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically searched PubMed, EMBASE.com, Web of Science, and Wiley\u2019s Cochrane library from inception to 29 January 2021. Eligible studies were randomized controlled trials, clinically controlled trials, prospective and retrospective cohort studies, and case\u2013control studies investigating the effects of [18F]FDG-PET\/CT in hospitalized adult patients with SAB. We excluded studies lacking a control group without [18F]FDG-PET\/CT. Risk of bias was assessed using the ROBINS-I tool and certainty of evidence using the GRADE approach by two independent reviewers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 1956 studies, of which five were included in our qualitative synthesis, including a total of 880 SAB patients. All studies were non-randomized and at moderate or serious risk of bias. Four studies, including a total of 804 patients, reported lower mortality in SAB patients that underwent [18F]FDG-PET\/CT. One study including 102 patients reported more detected metastatic foci in the participants in whom [18F]FDG-PET\/CT was performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>We found low certainty of evidence that [18F]FDG-PET\/CT reduces mortality in patients with SAB. This effect is possibly explained by a higher frequency of findings guiding optimal antibiotic treatment and source control interventions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07273-x","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T22:03:56Z","timestamp":1648159436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["[18F]FDG-PET\/CT in Staphylococcus aureus bacteremia: a systematic review"],"prefix":"10.1186","volume":"22","author":[{"given":"D. T. P.","family":"Buis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sieswerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. J. E.","family":"Kouijzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Y.","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. L.","family":"Burchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A. H.","family":"Berrevoets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. C. E.","family":"Sigaloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"issue":"3","key":"7273_CR1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603\u201361.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"7273_CR2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","volume":"25","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012;25(2):362\u201386.","journal-title":"Clin Microbiol Rev"},{"issue":"17","key":"7273_CR3","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","volume":"163","author":"VG Fowler Jr","year":"2003","unstructured":"Fowler VG Jr, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163(17):2066\u201372.","journal-title":"Arch Intern Med"},{"issue":"12","key":"7273_CR4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","volume":"20","author":"R Kuehl","year":"2020","unstructured":"Kuehl R, Morata L, Boeing C, Subirana I, Seifert H, Rieg S, et al. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis. 2020;20(12):1409\u201317.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"7273_CR5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"7273_CR6","first-page":"132","volume":"28","author":"H Ringberg","year":"2000","unstructured":"Ringberg H, Thor\u00e9n A, Lilja B. Metastatic complications of Staphylococcus aureus septicemia. To seek is to find Infection. 2000;28(3):132\u20136.","journal-title":"To seek is to find Infection"},{"issue":"2","key":"7273_CR7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10096-006-0238-4","volume":"26","author":"ML Cuijpers","year":"2007","unstructured":"Cuijpers ML, Vos FJ, Bleeker-Rovers CP, Krabbe PF, Pickkers P, van Dijk AP, et al. Complicating infectious foci in patients with Staphylococcus aureus or Streptococcus species bacteraemia. Eur J Clin Microbiol Infect Dis. 2007;26(2):105\u201313.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"7273_CR8","first-page":"255","volume":"9","author":"BT Kung","year":"2019","unstructured":"Kung BT, Seraj SM, Zadeh MZ, Rojulpote C, Kothekar E, Ayubcha C, et al. An update on the role of (18)F-FDG-PET\/CT in major infectious and inflammatory diseases. Am J Nucl Med Mol Imaging. 2019;9(6):255\u201373.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"5","key":"7273_CR9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/imj.14117","volume":"49","author":"AP Douglas","year":"2019","unstructured":"Douglas AP, Thursky KA, Worth LJ, Harrison SJ, Hicks RJ, Slavin MA. Access, knowledge and experience with fluorodeoxyglucose positron emission tomography\/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. Intern Med J. 2019;49(5):615\u201321.","journal-title":"Intern Med J"},{"key":"7273_CR10","doi-asserted-by":"crossref","first-page":"109168","DOI":"10.1016\/j.biopha.2019.109168","volume":"117","author":"WT Rahman","year":"2019","unstructured":"Rahman WT, Wale DJ, Viglianti BL, Townsend DM, Manganaro MS, Gross MD, et al. The impact of infection and inflammation in oncologic (18)F-FDG PET\/CT imaging. Biomed Pharmacother. 2019;117:109168.","journal-title":"Biomed Pharmacother."},{"issue":"5","key":"7273_CR11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12149-020-01449-8","volume":"34","author":"Y Li","year":"2020","unstructured":"Li Y, Wang Q, Wang X, Li X, Wu H, Wang Q, et al. Expert Consensus on clinical application of FDG PET\/CT in infection and inflammation. Ann Nucl Med. 2020;34(5):369\u201376.","journal-title":"Ann Nucl Med"},{"issue":"44","key":"7273_CR12","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"G Habib","year":"2015","unstructured":"Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075\u2013128.","journal-title":"Eur Heart J"},{"key":"7273_CR13","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"7273_CR14","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPT Higgins","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Tianjing L, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd ed. Hoboken: Wiley-Blackwell; 2019.","edition":"2"},{"key":"7273_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa929","author":"N Ghanem-Zoubi","year":"2020","unstructured":"Ghanem-Zoubi N, Kagna O, Abu-Elhija J, Mustafa-Hellou M, Qasum M, Keidar Z, et al. Integration of FDG-PET\/CT in the diagnostic workup for Staphylococcus aureus bacteremia: a prospective interventional matched-cohort study. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa929.","journal-title":"Clin Infect Dis"},{"key":"7273_CR16","unstructured":"Impact of 18 FDG PET\/CT on the management of patients with Staphylococcus aureus bloodstream infection. https:\/\/ClinicalTrials.gov\/show\/NCT03419221."},{"issue":"8","key":"7273_CR17","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.109.072371","volume":"51","author":"FJ Vos","year":"2010","unstructured":"Vos FJ, Bleeker-Rovers CP, Sturm PD, Krabbe PF, van Dijk AP, Cuijpers ML, et al. 18F-FDG PET\/CT for detection of metastatic infection in gram-positive bacteremia. J Nucl Med. 2010;51(8):1234\u201340.","journal-title":"J Nucl Med"},{"issue":"11","key":"7273_CR18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jiac.2019.04.016","volume":"25","author":"H Yildiz","year":"2019","unstructured":"Yildiz H, Reychler G, Rodriguez-Villalobos H, Orioli L, D\u2019Abadie P, Vandeleene B, et al. Mortality in patients with high risk Staphylococcus aureus bacteremia undergoing or not PET-CT: a single center experience. J Infect Chemother. 2019;25(11):880\u20135.","journal-title":"J Infect Chemother"},{"issue":"9","key":"7273_CR19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2967\/jnumed.117.191981","volume":"58","author":"MAH Berrevoets","year":"2017","unstructured":"Berrevoets MAH, Kouijzer IJE, Aarntzen E, Janssen MJR, De Geus-Oei LF, Wertheim HFL, et al. (18)F-FDG PET\/CT optimizes treatment in Staphylococcus aureus bacteremia and is associated with reduced mortality. J Nucl Med. 2017;58(9):1504\u201310.","journal-title":"J Nucl Med"},{"issue":"7","key":"7273_CR20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2967\/jnumed.118.221929","volume":"60","author":"MAH Berrevoets","year":"2019","unstructured":"Berrevoets MAH, Kouijzer IJE, Slieker K, Aarntzen E, Kullberg BJ, Oever JT, et al. (18)F-FDG PET\/CT-guided treatment duration in patients with high-risk Staphylococcus Aureus bacteremia: a proof of principle. J Nuclear Med. 2019;60(7):998\u20131002.","journal-title":"J Nuclear Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07273-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07273-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07273-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T11:25:14Z","timestamp":1648207514000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07273-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7273"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07273-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"8 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Kim C.E. Sigaloff has received funding to study the optimal duration for <i>S. aureus<\/i> bacteremia from The Netherlands Organisation for Health Research and Development. No other potential conflicts of interest relevant to this article exist. Other authors have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}